Friday 6 November 2026 Export CYTK’s income statement to Excel — free account

Cytokinetics, Incorporated

Cytokinetics, Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $88.0 million, up 376.6% from fiscal 2024.

Revenue: +2,356.5%
EPS: +46.3%
Free cash flow: −6.73%
Total debt: −83.9%

Quarter to September 2026, against a year earlier

54.93 0.62 −1.12%

Follow CYTK

Alert me

Market cap: $7.7B
P/E: 0.0×
Fwd P/E: −10.3×
Dividend yield: —
F-score: 2/9
Altman Z: −1.98
Beneish M: −0.44
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Cytokinetics, Incorporated (CYTK) P/B ratio

Alert me on P/B ratio

Cytokinetics, Incorporated has no meaningful P/B ratio: its trailing twelve-month book value is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 183× (June 2019) — the current reading is the lowest in ten years.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/CYTK/pb-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Cytokinetics, Incorporated P/B ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/CYTK/metrics/pb-ratio">Cytokinetics, Incorporated (CYTK) P/B ratio — stockrow.com</a></p>

Period	P/B ratio	Change
FY2025	0.0×	—
FY2024	0.0×	—
FY2023	0.0×	—
FY2022	0.0×	—
FY2021	14.4×	21.52%
FY2020	11.8×	—
FY2019	0.0×	—
FY2018	13.3×	236.98%
FY2017	3.9×	(25.02%)
FY2016	5.2×	(11.32%)

Period	P/B ratio	Change
Sep 2026	0.0×	—
Jun 2026	0.0×	—
Mar 2026	0.0×	—
Dec 2025	0.0×	—
43 more quarters	Free account

Against its own ten years

Low 0.0× High 183×

Ten-year median 3.5×

Current reading's percentile 43

Company	P/B ratio
CYTK Cytokinetics, Incorporated	n/m
KRYS Krystal Biotech, Inc. compare	6.2×
CORT Corcept Therapeutics Incorporated compare	9.2×
SYRE Spyre Therapeutics, Inc. compare	9.5×
PTGX Protagonist Therapeutics, Inc. compare	10.6×
CAI Caris Life Sciences,�Inc. compare	12.7×
TWST Twist Bioscience Corporation compare	17.1×
ARWR Arrowhead Pharmaceuticals, Inc. compare	17.7×
MDGL Madrigal Pharmaceuticals, Inc. compare	18.7×
Biotechnology industry median	2.0×
Healthcare sector median	2.3×
Market median	1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

Cytokinetics, Incorporated (CYTK) P/B ratio

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on CYTK

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on CYTK

Stockrow Weekly